A Phase 4, multicenter, prospective, non-interventional, observational study to investigate the effectiveness and safety/tolerability of perampanel when used as first adjunctive therapy in routine clinical practice in people with epilepsy: Study 512
PER was efficacious for focal and generalized seizures across all age groups and was generally well-tolerated, as demonstrated by the high retention rates at 12 months.
Authors
- Anna Patten (ORCID: https://orcid.org/0000-0002-1319-8680)
- С. Г. Бурд (ORCID: https://orcid.org/0000-0003-0804-7076)
- А. В. Лебедева (ORCID: https://orcid.org/0000-0001-8712-4775)
- Ricardo Sáinz‐Fuertes (ORCID: https://orcid.org/0000-0003-0980-5748)
- Stanislas Lagarde (ORCID: https://orcid.org/0000-0003-2916-1302)
- Jan Wagner (ORCID: https://orcid.org/0000-0002-0459-8885)
- Samantha Goldman
- Tobias Sejbæk (ORCID: https://orcid.org/0000-0002-7682-2188)
- Giovanni Assenza (ORCID: https://orcid.org/0000-0003-3129-1982)
- П. Н. Власов (ORCID: https://orcid.org/0000-0001-8321-5864)
- Sofia Quintas
- Francisco J. López
- Vadim Kharkovsky
- N V Pantina
- Marta Torres Arlandis
Institutions
- Inserm (FR)
- Università Campus Bio-Medico (IT)
- University of Southern Denmark (DK)
- Pirogov Russian National Research Medical University (RU)
- Institut de Neurosciences des Systèmes (FR)
- Centro Hospitalar Lisboa Norte (PT)
- Hospital Universitari Sagrat Cor (ES)
- Hospital South West Jutland (DK)
- University and Rehabilitation Clinics Ulm (DE)
- Campus Bio Medico University Hospital (IT)
- Eisai (United Kingdom) (GB)
- National Research Institute of Public Health named after N.A. Semashko (RU)
- Research Center of Neurology (RU)
- Hôpital de la Timone (FR)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-04-15
- DOI
- https://doi.org/10.3389/fneur.2025.1533767
- Citations
- 1
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Eisai